LifeSci Capital initiated coverage of Revolution Medicines (RVMD) with an Outperform rating and $80 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Target downgraded, Salesforce upgraded: Wall Street’s top analyst calls
- Revolution Medicines initiated with an Overweight at Wells Fargo
- Revolution Medicines’ Innovative RAS(ON) Platform and Strategic Collaborations Drive Buy Rating
- Revolution Medicines’ Earnings Call: Progress Amid Challenges
- Optimistic Outlook for Revolution Medicines Amid Strategic Developments and Pipeline Progress